Moderna FY2024 EPS Decreased by Brookline Capital Management

Moderna, Inc. (NASDAQ:MRNA) – Stock analysts at Brookline Capital Management lowered their FY2024 earnings per share estimates for shares of Moderna in a research note issued to investors on Monday, January 13th. Brookline Capital Management analyst L. Cann now forecasts that the company will post earnings of ($9.15) per share for the year, down from their prior forecast of ($9.12). The consensus estimate for Moderna’s current full-year earnings is ($9.30) per share. Brookline Capital Management also issued estimates for Moderna’s Q4 2024 earnings at ($2.85) EPS, FY2025 earnings at ($8.56) EPS, FY2026 earnings at ($2.00) EPS, FY2027 earnings at $1.30 EPS and FY2028 earnings at $5.31 EPS.

A number of other equities research analysts have also weighed in on the stock. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $75.00 target price on shares of Moderna in a research note on Thursday, September 19th. Jefferies Financial Group reduced their target price on Moderna from $65.00 to $55.00 and set a “hold” rating on the stock in a report on Tuesday, October 15th. Argus lowered Moderna from a “buy” rating to a “hold” rating in a research report on Wednesday, December 18th. Berenberg Bank began coverage on Moderna in a research report on Tuesday, November 19th. They set a “hold” rating and a $42.00 price target on the stock. Finally, Morgan Stanley decreased their price objective on Moderna from $70.00 to $38.00 and set an “equal weight” rating for the company in a report on Wednesday. Four research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $76.68.

Moderna Stock Up 0.9 %

Shares of Moderna stock opened at $34.77 on Thursday. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 4.20. Moderna has a 12-month low of $31.94 and a 12-month high of $170.47. The company’s fifty day simple moving average is $41.44 and its two-hundred day simple moving average is $67.56.

Moderna (NASDAQ:MRNA) last posted its earnings results on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.89) by $1.92. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The firm had revenue of $1.90 billion for the quarter, compared to analysts’ expectations of $1.25 billion. During the same period in the previous year, the firm earned ($1.39) earnings per share. The business’s revenue was up 3.8% compared to the same quarter last year.

Institutional Investors Weigh In On Moderna

Large investors have recently bought and sold shares of the business. Axiom Advisory LLC lifted its stake in Moderna by 1.6% during the 3rd quarter. Axiom Advisory LLC now owns 12,672 shares of the company’s stock valued at $847,000 after acquiring an additional 198 shares during the period. Ashton Thomas Private Wealth LLC bought a new position in Moderna during the second quarter valued at approximately $26,000. Arkadios Wealth Advisors boosted its holdings in Moderna by 2.2% in the third quarter. Arkadios Wealth Advisors now owns 11,429 shares of the company’s stock worth $764,000 after purchasing an additional 243 shares during the last quarter. Knuff & Co LLC grew its position in Moderna by 5.4% in the 3rd quarter. Knuff & Co LLC now owns 4,732 shares of the company’s stock worth $316,000 after purchasing an additional 244 shares during the period. Finally, Stephens Inc. AR grew its position in Moderna by 7.9% in the 3rd quarter. Stephens Inc. AR now owns 3,334 shares of the company’s stock worth $223,000 after purchasing an additional 245 shares during the period. 75.33% of the stock is currently owned by institutional investors.

Insider Activity

In other news, insider Shannon Thyme Klinger sold 1,418 shares of the business’s stock in a transaction on Friday, November 29th. The stock was sold at an average price of $42.79, for a total value of $60,676.22. Following the completion of the transaction, the insider now owns 19,717 shares in the company, valued at $843,690.43. The trade was a 6.71 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders have sold a total of 2,664 shares of company stock worth $115,210 over the last 90 days. 15.20% of the stock is currently owned by insiders.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.